Introduction
Advanced heart failure remains a leading cause of death worldwide, with many patients facing limited treatment options. For those who are not immediate candidates for heart transplantation or are ineligible for transplant, mechanical circulatory support devices have become vital life-saving therapies. These therapies include Bridge to Transplant (BTT) and Destination Therapy (DT)—two distinct strategies that utilize ventricular assist devices (VADs) and other technologies to support cardiac function. At Neftaly, we are committed to advancing heart failure care by promoting innovation, education, and equitable access to these transformative treatments.
Understanding Bridge to Transplant and Destination Therapy
- Bridge to Transplant (BTT): Mechanical circulatory support used temporarily to stabilize patients with end-stage heart failure while they await heart transplantation. BTT improves survival and quality of life during this waiting period.
- Destination Therapy (DT): Long-term use of mechanical support devices for patients who are not candidates for heart transplant, providing durable treatment and significantly extending life expectancy.
Clinical Impact
✅ Improved Survival Rates
Both BTT and DT have revolutionized the prognosis for patients with advanced heart failure, offering a chance for extended survival where medical therapy alone is insufficient.
✅ Enhanced Quality of Life
Patients supported by VADs often experience symptom relief, improved exercise capacity, and better functional status.
✅ Reduced Hospitalizations
Mechanical support reduces the frequency and duration of hospital admissions for heart failure exacerbations.
Challenges and Considerations
- Device-Related Complications: Risks include infection, bleeding, thrombosis, and device malfunction, necessitating rigorous monitoring and multidisciplinary care.
- Patient Selection: Careful assessment is critical to determine appropriate candidates for BTT versus DT.
- Cost and Access: High costs and the need for specialized infrastructure can limit availability, especially in low-resource settings.
Neftaly’s Role in Advancing Therapy
???? Training and Capacity Building
Neftaly offers education programs for cardiologists, surgeons, nurses, and support staff on patient selection, device management, and complication prevention.
???? Research and Innovation
We collaborate with research centers to optimize device technology, refine clinical protocols, and improve long-term outcomes.
???? Expanding Access Globally
Neftaly partners with health systems to develop mechanical circulatory support programs, focusing on underserved regions and improving equity in advanced heart failure care.
Conclusion
Bridge to Transplant and Destination Therapy represent groundbreaking advances in the treatment of advanced heart failure, transforming patient outcomes and quality of life. With ongoing innovation and global collaboration, these therapies continue to offer hope to patients previously facing limited options.
At Neftaly, we are proud to support the global heart failure community by promoting knowledge, advancing technology, and expanding access to these life-saving treatments.
Neftaly: Empowering Lives with Advanced Heart Failure Solutions.